#None #Hyphens Pharma #Cerapro #Dermatitis

Hyphens Pharma Takes a Major Step in European Dermatology

Hyphens Pharma International Limited, based in Singapore, has made significant strides in the dermatology market with the upcoming release of its innovative product, Cerapro® MED Skin Barrier Cream. This pioneering cream is set to be launched in six key European markets: Switzerland, Austria, the Netherlands, Belgium, Luxembourg, and Liechtenstein. This strategic move marks a pivotal expansion for Hyphens Pharma as it partners with Louis Widmer SA, a renowned player in the pharmaceutical and cosmetic industry, to introduce this groundbreaking product.

The product, Cerapro®, is designed to address atopic dermatitis, a prevalent form of eczema that affects countless individuals, particularly children. Managing skin pH levels is vital for alleviating symptoms, as a higher pH can exacerbate the condition. Cerapro® stands out with its patented formula that effectively reduces skin pH while simultaneously restoring the skin barrier, thus offering a new therapeutic approach to managing eczema.

Cerapro® has earned recognition as a CE-marked medical device, compliant with the rigorous European Regulations on Medical Devices (MDR). This approval is a testament to the product's efficacy and safety, ensuring that patients and healthcare providers can have confidence in its therapeutic potential.

The collaboration with Louis Widmer is significant for both entities. Founded in 1960 and based in Switzerland, Louis Widmer is known for its high-quality dermatological products. Under the licensing agreement, Louis Widmer will be responsible for the marketing and promotion of Cerapro® among dermatologists and pediatricians in the designated markets. This partnership aligns with both companies' commitment to scientific-backed innovations that aim to enhance patient outcomes.

Lim See Wah, the CEO and President of Hyphens Pharma, expressed enthusiasm about the collaboration, stating, "This important partnership with Louis Widmer underscores our commitment to innovation and patient care. Leveraging Louis Widmer’s established presence and expertise in dermatology, we aim to make Cerapro® accessible to patients across Europe while we continue to explore new growth opportunities."

Announcing the partnership, Annemarie Widmer, CEO of Louis Widmer, also spoke about the synergy of their combined efforts. "We are excited to partner with Hyphens Pharma to bring Cerapro® to our markets, providing patients with a clinically validated solution for atopic dermatitis. This will be the flagship product of our Remederm line, which is well-regarded among both retail and medical professionals for treating dry, very dry, and atopic skin conditions."

As Hyphens Pharma prepares to enter these new markets in 2026, it aims to not only provide an effective solution for skin health but also to establish a robust operational framework capable of supporting distribution and product education for healthcare professionals. This strategy reflects Hyphens' mission of improving life quality through enhanced accessibility to innovative healthcare products.

In summary, the introduction of Cerapro® MED Skin Barrier Cream in the European market marks a significant advance in the treatment options available for atopic dermatitis, reinforcing Hyphens Pharma’s role as a leader in specialized pharmaceuticals and consumer healthcare. With its strong commitment to research and development, the company is well-positioned to expand its influence in the dermatological sector and improve outcomes for patients suffering from skin conditions across Europe.